Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LX7101 (0.125%)
LX7101 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Low dose LX7101 | EXPERIMENTAL | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| High dose LX7101 | EXPERIMENTAL | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| LX7101 Vehicle | PLACEBO_COMPARATOR | Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye) |
| Name | Type | Description |
|---|---|---|
| LX7101 (0.125%) | DRUG | Subjects will receive 0.125% LX7101 |
| LX7101 (0.25%) | DRUG | Subjects will receive 0.25% LX7101 |
| LX7101 Vehicle | DRUG | Subjects will receive vehicle |
Inclusion Criteria: * Adults ≥18 years of age * Documented diagnosis of POAG or OHT, in both eyes * Willing and able to provide written informed consent Exclusion Criteria: * History of any form of glaucoma in either eye, other than POAG * Subjects who are unwilling or unable to discontinue conta...
LX7101 is an investigational small molecule developed by Lexicon Pharmaceuticals, Inc. (ticker LXRX) for Primary Open-angle Glaucoma. It is a topical ophthalmic formulation, referenced as LX7101 (0.125%), and is in Phase 1 clinical development. It has been studied in a single completed Phase 1 trial.
LX7101 is being developed for Primary Open-angle Glaucoma, a condition involving elevated intraocular pressure and optic nerve damage. The completed Phase 1 study also enrolled subjects with Ocular Hypertension. It is investigational and has not been approved for commercial use in this or any other indication.
LX7101 is developed by Lexicon Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker LXRX. Lexicon is the sponsor of the clinical program evaluating the compound in ophthalmology. The asset is a small molecule formulation designated LX7101 (0.125%).
LX7101 is in Phase 1 clinical development. Its only recorded trial, NCT01528111, is a completed Phase 1 study, and no active trials are currently listed. Because it remains investigational, LX7101 has not received FDA approval for Primary Open-angle Glaucoma or any other indication.
LX7101 has been evaluated in one clinical trial, NCT01528111, titled a study to evaluate the safety, tolerability, and efficacy of LX7101 in subjects with Primary Open-angle Glaucoma or Ocular Hypertension. The Phase 1 trial was randomized, double-blind, and placebo-controlled, enrolled 63 participants in the United States, and is completed.
Yes. LX7101 (0.125%) is an alternative designation for LX7101, referring to the 0.125% concentration of the ophthalmic formulation used in its clinical program. Both names refer to the same investigational small molecule developed by Lexicon Pharmaceuticals, Inc. for Primary Open-angle Glaucoma.